Effects of a Novel Glucokinase Activator, Dorzagliatin, on Glycemic Control and Glucose Fluctuation in Drug-Naïve Patients with Type 2 Diabetes Mellitus

Table 2

Glucose fluctuation parameters of the patients before and after intervention.

	Before	After	value
MBG (mmol/L)	10.21 ± 2.07	8.52 ± 1.75	0.002
SDBG (mmol/L)	2.00 ± 0.71	1.46 ± 0.77	0.006
MAGE (mmol/L)	5.18 ± 1.92	3.65 ± 1.73	0.003
LAGE (mmol/L)	7.96 ± 2.65	5.98 ± 2.42	0.008
ADRR	1.63 ± 0.36	1.16 ± 0.43	<0.001
LBGI	0 (0, 0.12)	0.07 (0, 0.99)	0.091
HBGI	9.08 (4.81, 15.09)	4.66 (1.61, 8.47)	0.002
TIR (3.9−10 mmol/L, %)	66.84 (22.40, 80.90)	89.58 (58.07, 98.96)	0.005
TAR (>10 mmol/L, %)	33.16 (19.10, 77.60)	9.72 (0, 41.93)	0.004
TBR (<3.9 mmol/L, %)	0 (0, 0)	0 (0, 0)	0.180

MBG: mean blood glucose (mmol/L); SDBG: standard deviation of mean blood glucose (mmol/L); MAGE: mean amplitude of glycemic excursions (mmol/L); LAGE: largest amplitude of glycemic excursions (mmol/L); ADRR: average daily risk range; LBGI: low blood glucose index; HGBI: high blood glucose index; TIR: time in range: percentage of time in the range of 3.9–10 mmol/L; TAR: time above range: percentage of time >10 mmol/L; TBR: time below range: percentage of time <3.9 mmol/L. Continuous variables with normal distribution were presented as mean ± SD; non-normal variables are shown as median (interquartile range).